2,6 Millionen Euros fot the Charité Berlin
Cancer can be caused by a variety of genetic mutations. One challenge medicine faces is finding tailor-made treatment for each patient based on their individual genetic differences. Scientists at the German Cancer Consortium (DKTK) at the Charité Comprehensive Cancer Center in Berlin have now received 2.6 million Euros so, together with regional biotechnology companies, they can make test systems available for personalized medication screening. The German Cancer Consortium (DKTK) builds a strong, long-term, institutional structure between the German Cancer Research Center (DKFZ) and universities and university hospitals all over Germany specially designated to clinical oriented cancer research.
Please read the news here.
Back to Overview